TRANSLATIONAL PATHOLOGY SHARED RESOURCE The TP facility is a multi-component SR that integrates human and non-human histopathology services to facilitate and coordinate studies for LCCC members. TP provides expertise and techniques focused on either pre-clinical (AHC) or clinical (TPL) specimens and facilitates translation of results between the two. Each component is led by board-certified faculty pathologist (MD, DVM, PhD) who oversees operations and long- term planning. AHC provides comprehensive animal pathology support to investigators, from study design through specimen handling, grossing, routine and specialized histologic techniques, bloodwork, urinalysis, molecular characterization of tissue, and tissue morphologic analysis. The AHC component director Stephanie Montgomery, DVM, PhD is expanding the core and its capabilities by initiating a novel training program in veterinary pathology in combination with UNC sister University NC State and its Veterinary School. TPL, under Dr. Sara Wobker, MD, supports clinical studies by providing access to formalin-fixed, paraffin-embedded tissues from UNC Hospitals Surgical Pathology archives, start-to-finish translational pathology project management, and histopathology services. Both components are equipped with instrumentation for routine pathology but have upgrades for high level digital pathology and analysis. New technology for single cell analysis including the Geo Max from Nanostring is being incorporated into the SR to aid in understanding the tumor microenvironment. The facility is well used by 109 total users of which 78 (72%) are Center members. The facility is well- supported by chargebacks, receiving 57% of their fiscal year 2019 operating revenue from that source. TP is requesting $186,872 from the CCSG or 12% of the operating budget. TP has supported 200 peer-reviewed publications during the last funding cycle of the CCSG including cancer therapeutics, immunotherapy, nutrition and cancer, nanotechnology, cancer cell signaling, gene therapy, novel cancer models, and personalized medicine.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Chapel Hill
United States
Zip Code
Cholon, Deborah M; Gentzsch, Martina (2018) Recent progress in translational cystic fibrosis research using precision medicine strategies. J Cyst Fibros 17:S52-S60
Tappata, Manaswita; Eluri, Swathi; Perjar, Irina et al. (2018) Association of mast cells with clinical, endoscopic, and histologic findings in adults with eosinophilic esophagitis. Allergy 73:2088-2092
Che, Tao; Majumdar, Susruta; Zaidi, Saheem A et al. (2018) Structure of the Nanobody-Stabilized Active State of the Kappa Opioid Receptor. Cell 172:55-67.e15
Hu, Peirong; Bi, Yanmin; Ma, Hong et al. (2018) Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization. Gene Ther 25:454-472
Townsley, Loni; Yannarell, Sarah M; Huynh, Tuanh Ngoc et al. (2018) Cyclic di-AMP Acts as an Extracellular Signal That Impacts Bacillus subtilis Biofilm Formation and Plant Attachment. MBio 9:
Schulfer, Anjelique F; Battaglia, Thomas; Alvarez, Yelina et al. (2018) Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 3:234-242
Hall, Marissa G; Mendel, Jennifer R; Noar, Seth M et al. (2018) Why smokers avoid cigarette pack risk messages: Two randomized clinical trials in the United States. Soc Sci Med 213:165-172
van Haren, Jeffrey; Charafeddine, Rabab A; Ettinger, Andreas et al. (2018) Local control of intracellular microtubule dynamics by EB1 photodissociation. Nat Cell Biol 20:252-261
Gopal, Satish; Gross, Thomas G (2018) How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood 132:254-263
Deng, Jiehui; Wang, Eric S; Jenkins, Russell W et al. (2018) CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov 8:216-233

Showing the most recent 10 out of 1525 publications